Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives $19.40 Consensus PT from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has been given an average rating of “Hold” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $19.40.

Several research firms have commented on TBPH. BTIG Research lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday, June 29th. Wall Street Zen cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a report on Monday, June 29th. Weiss Ratings upgraded Theravance Biopharma from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 3rd. Finally, HC Wainwright lowered Theravance Biopharma from a “buy” rating to a “neutral” rating and raised their target price for the stock from $15.00 to $17.00 in a report on Tuesday, July 7th.

Theravance Biopharma Price Performance

TBPH stock opened at $16.93 on Monday. The company has a market capitalization of $872.74 million, a P/E ratio of 7.70 and a beta of 0.19. Theravance Biopharma has a 12 month low of $11.20 and a 12 month high of $21.03. The firm’s fifty day simple moving average is $16.77 and its 200-day simple moving average is $16.91.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $17.70 million for the quarter. Theravance Biopharma had a return on equity of 18.84% and a net margin of 104.34%. As a group, sell-side analysts forecast that Theravance Biopharma will post 1.56 earnings per share for the current year.

Insider Buying and Selling

In other Theravance Biopharma news, major shareholder Eli Samaha sold 273,871 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $17.23, for a total value of $4,718,797.33. Following the sale, the insider owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $16.39, for a total transaction of $218,216.46. Following the sale, the senior vice president directly owned 232,457 shares in the company, valued at $3,809,970.23. The trade was a 5.42% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 350,011 shares of company stock valued at $6,008,309 over the last three months. 7.65% of the stock is currently owned by corporate insiders.

Institutional Trading of Theravance Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TBPH. Vanguard Group Inc. raised its position in shares of Theravance Biopharma by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after acquiring an additional 54,152 shares during the period. State Street Corp boosted its stake in shares of Theravance Biopharma by 4.4% during the 4th quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock worth $20,616,000 after acquiring an additional 45,987 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Theravance Biopharma by 14.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 983,615 shares of the biopharmaceutical company’s stock valued at $15,960,000 after acquiring an additional 124,658 shares during the period. Geode Capital Management LLC grew its position in shares of Theravance Biopharma by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after acquiring an additional 40,734 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Theravance Biopharma in the 3rd quarter valued at about $10,611,000. Institutional investors and hedge funds own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.